PerpEquities

Medline Inc. (MDLN) financials

NASDAQ · Healthcare · Medical - Instruments & Supplies · 45,000 employees · CEO James Boyle

Price
$37.55 0.0%
Market cap
$32.5B
Enterprise value
$42.8B Data as of 2026-11-22
Last report
Q3 '26 filed 2026-11-04
Next report
2027-02-24 EPS est. $0.39
Revenue (TTM)$30.7B– vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)5.7%– vs a year agoOperating income $1.74B
Net income (TTM)$564M– vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$1.9B– vs a year agoCapex $486M
Diluted EPS (TTM)$0.67– vs a year agoSum of the last 4 quarters
Net cash-$8.97B+42.8% vs a year agoCash + short-term investments - debt

Valuation & key figures

Market cap
$32.5B
Updated 1h ago
Revenue
$30.7B
Trailing 12 months
Revenue growth
+10%
FY2026 consensus
Profit margin
1.8%
Net income / revenue, TTM
P/E
55.3×
Forward 24.2× (FY2026)
P/S
1.1×
Price / sales, TTM
EV / EBITDA
16.4×
TTM
Free cash flow
$1.9B
Trailing 12 months
Net income
$564M
Trailing 12 months
Revenue estimate
$31.4B
FY2026 consensus
Earnings
2027-02-24
Revenue est. $8.5B · Updated 1h ago
Dividend
–
No dividend

Key takeaways

Computed from the reported numbers - every statement carries the figure it rests on.

  • Last report (2026-11-04): revenue beat by 1.7%, EPS beat by 28.2%Revenue $7.86B vs $7.72B expected (+1.7%); EPS $0.44 vs $0.34 (+28.2%).
  • Revenue growth steady: 10.4% year on yearQ3 '26 revenue $7.86B, against an average of 11.2% over the four quarters before.
  • 55.8% of pre-tax profit is eaten by non-operating lossesPre-tax income $1.12B vs operating income $1.74B (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.
  • Capex 1.6% of revenue$486M invested in the last 4 quarters (– on a year earlier). Free cash flow $1.9B = 336.0% of net income.
  • Returned $2.07B to shareholders = 109.0% of free cash flowBuybacks $1.97B (a year earlier –), dividends $96M, stock-based pay $81M (TTM). More than the free cash flow: paid from cash or debt.
  • Diluted share count up 67.2% in a year1.32B diluted shares in Q3 '26, 787M a year earlier.
  • Net debt $8.97BCash + short-term investments $3.61B, debt incl. leases $12.6B; a year ago net debt $15.7B.

Last quarter: Q3 '26

Quarter ended 2026-09-26. Compared with the same quarter a year earlier and with the analyst consensus before the report.

Quarter vs a year ago

Q3 '26Year agoChange
Revenue$7.86B$7.12B+10.4%
Gross margin24.5%23.9%+0.6 pp
Operating income$500M$574M-12.9%
Operating margin6.4%8.1%-1.7 pp
Net income$195M$322M-39.4%
Diluted EPS$0.22$0.41-46.3%
Operating cash flow$1.03B$636M+61.2%
Capex$141M$101M+39.6%
Free cash flow$884M$535M+65.2%
R&D$0$0–
Stock-based compensation$52M$0–

Reported vs consensus

2026-11-04
ActualConsensusvs consensus
Revenue$7.86B$7.72B+1.7%
EPS (as estimated)$0.44$0.34+28.2%

From the report of 2026-11-04 for Q3 '26: revenue and the EPS analysts estimate (often adjusted), so it can differ from the EPS of the statements above.

EPS vs consensus

last 8 reports

Revenue

Where the money comes from - by business line and by region, quarter by quarter.

Revenue, operating income and growth

quarterly

Revenue by region

share of the listed regions
SegmentQ3 '26y/yShare of listedTTMTTM y/y12 quarters
United States$7.34B–93.4%––
Non-US$518M–6.6%––

Margins & cost structure

How much of each unit of revenue is left at each level - and where the costs go.

Margins

quarterly

Costs as % of revenue

quarterly

Cash flow & capital allocation

Cash generated, what it is spent on, and what reaches shareholders.

Operating cash flow, capex, free cash flow

quarterly

Uses of cash vs operating cash flow

fiscal years

Last 4 quarters

cash flow statement
Operating cash flow
$2.38B
Capex
-$486M
Buybacks
-$1.97B
Dividends
-$96M
Acquisitions
$0
Net debt issued
-$4.09B
Stock-based compensation
$81M
Free cash flow
$1.9B
Returned to shareholders / FCF
109.0%

Share count and EPS

quarterly, diluted

Balance sheet

Liquidity, investments and debt at each quarter end.

Cash, investments and debt

quarter ends

Valuation & returns

Today's multiples against the company's own last five fiscal years; analyst targets and ratings.

Multiples and returns

TTM vs 5 fiscal years
Now5y averageWhere today sits in the 5-year range
P/E (TTM)55.3×64.3× 3 of 4 years27.0× – 136.7×
EV / EBITDA16.4×18.3× 3 of 4 years15.0× – 20.2×
EV / Sales1.4×1.8× 3 of 4 years1.6× – 2.0×
Price / FCF17.2×24.1× 3 of 4 years22.9× – 26.3×
Price / Book2.8×2.3× 3 of 4 years1.9× – 3.2×
FCF yield5.8%3.1%-0.2% – 4.4%
Return on invested capital3.7%3.8%0.0% – 6.1%
Return on equity5.0%4.9%0.0% – 10.8%

Analysts

Consensus target $44.20 (+19.3%)
range $37.00 – $55.00 · rating Buy

Strong buy0
Buy17
Hold2
Sell0
Strong sell0

Outlook

Analyst consensus for the coming fiscal years and what it implies at today's price.

Consensus estimates

Fiscal yearRevenueGrowthEPSGrowthP/E at today's priceAnalysts (EPS)
FY2026$31.4B+10.4%$1.55+8.6%24.2×13
FY2027$34B+8.2%$1.57+0.9%24.0×14
FY2028$36.7B+8.0%$1.76+12.5%21.3×8
FY2029$39.5B+7.8%$2.02+14.8%18.6×5
FY2030$42.5B+7.6%$2.25+11.3%16.7×5

Financial statements

Every line of the income statement, balance sheet and cash flow statement - 12 quarters and 10 fiscal years, as values, as % of revenue or as growth.

Every reported line

All 324 figures Medline Inc. tagged in its recent 10-Q / 10-K filings, with the official SEC label and definition - including the notes (leases, taxes, buybacks, employees, ...).

Line (SEC label)Latest quarterYear agoy/yLatest FYPrior FYy/y
Accounts Payable, Current$1.21B––$961M$869M+10.6%
Accounts Receivable, after Allowance for Credit Loss, Current$3.79B––$3.53B$3.22B+9.8%
Accounts Receivable, Allowance for Credit Loss, Current$148M––$152M$108M+40.7%
Accounts Receivable, Credit Loss Expense (Reversal)$4M$6M-33.3%$54M$63M-14.3%
Accrual for Taxes Other than Income Taxes$82M––$87M$83M+4.8%
Accrued Income Taxes, Current$16M2026-06-27––$24M$4M+500.0%
Accrued Liabilities, Current$1.89B––$1.45B$1.49B-2.7%
Accrued Salaries, Current$483M––$323M$330M-2.1%
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment$1.16B2025-12-31$861M+34.8%$1.16B$861M+34.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax-$4M––$27M$11M+145.5%
Additional Paid in Capital$11.4B––$10.7B––
Amortization of Debt Issuance Costs$10M$15M-33.3%$59M$57M+3.5%
Amortization of Intangible Assets$176M$177M-0.6%$704M$685M+2.8%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount2.22M–––––
APIC, Share-based Payment Arrangement, Increase for Cost Recognition$29M–––––
Asset Impairment Charges–––$0––
Assets$40.2B––$38.5B$36B+7.0%
Assets, Current$12.7B––$10.7B$8.27B+29.1%
Assets, Fair Value Disclosure$1.3B–––––
Business Combination, Contingent Consideration, Liability$29M–––––
Capital Expenditures Incurred but Not yet Paid-$24M-$22M-9.1%$58M$50M+16.0%
Cash and Cash Equivalents, at Carrying Value$2.32B––$1.94B$199M+874.4%
Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months-$9M––$34M––
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents$2.32B$955M+143.2%$1.94B$250M+676.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect-$6M$371M-101.6%$1.69B-$1.34B+226.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest$124M$0–-$2M$0–
Comprehensive Income (Loss), Net of Tax, Attributable to Parent$197M$312M-36.9%$1.19B$1.02B+16.4%
Cost of Goods and Services Sold$5.93B$5.24B+13.2%$20.9B$18.5B+12.9%
Current Federal Tax Expense (Benefit)–––$24M$6M+300.0%
Current Foreign Tax Expense (Benefit)–––$83M$58M+43.1%
Current Income Tax Expense (Benefit)–––$111M$70M+58.6%
Current State and Local Tax Expense (Benefit)–––$4M$6M-33.3%
Debt Issuance Costs, Net$164M––$195M$265M-26.4%
Debt, Current$29M––$77M$78M-1.3%
Deferred Federal Income Tax Expense (Benefit)–––$4M$0–
Deferred Foreign Income Tax Expense (Benefit)–––-$24M-$24M0.0%
Deferred Income Tax Assets, Net$833M––$583M$0–
Deferred Income Tax Expense (Benefit)$39M-$3M+1,400.0%-$20M-$24M+16.7%
Deferred State and Local Income Tax Expense (Benefit)–––$0$0–
Deferred Tax Asset, Interest Carryforward$142M2025-12-31$0–$142M$0–
Deferred Tax Assets, Net$384M2025-12-31––$384M––
Deferred Tax Assets, Net of Valuation Allowance$747M2025-12-31$28M+2,567.9%$747M$28M+2,567.9%
Deferred Tax Assets, Other$8M2025-12-31$4M+100.0%$8M$4M+100.0%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits$14M2025-12-31$13M+7.7%$14M$13M+7.7%
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities$17M2025-12-31$10M+70.0%$17M$10M+70.0%
Deferred Tax Assets, Valuation Allowance$215M––$0$1M-100.0%
Deferred Tax Liabilities, Gross$363M2025-12-31$223M+62.8%$363M$223M+62.8%
Deferred Tax Liabilities, Intangible Assets$170M2025-12-31$183M-7.1%$170M$183M-7.1%
Deferred Tax Liabilities, Inventory$02025-12-31$1M-100.0%$0$1M-100.0%
Deferred Tax Liabilities, Investments$157M2025-12-31$0–$157M$0–
Deferred Tax Liabilities, Net–––$195M2024-12-31––
Deferred Tax Liabilities, Other$2M2025-12-31$2M0.0%$2M$2M0.0%
Deferred Tax Liabilities, Property, Plant and Equipment$34M2025-12-31$37M-8.1%$34M$37M-8.1%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate7.4%2025-12-317.0%+5.9%7.4%7.0%+5.9%
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase4.5%2025-12-314.4%+3.2%4.5%4.4%+3.2%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate–––7.0%6.3%+11.5%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets–––3.3%3.5%-5.8%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase–––4.4%4.3%+0.2%
Defined Benefit Plan, Benefit Obligation$61M2025-12-31$49M+24.5%$61M$49M+24.5%
Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years$42M2025-12-31––$42M––

Source: SEC companyfacts (XBRL of every 10-Q / 10-K). Cash-flow quarters are derived from the year-to-date figures the 10-Q tags. Segment breakdowns are tagged with dimensions and are shown in the segment section instead.

Sources

Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-26, 10-Q 2026-06-27, 10-Q 2026-03-28, 10-K 2025-12-31

Data as of 2026-11-22